AVXL Anavex Life Sciences

XNAS 1.28 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

AVXL $1.28 —
Key stats
$1.28
52-Week Range
$1.14 – $8.79
YTD
-65.22%
Straddle Price
$0.80
P/C Vol Ratio
0.05
Market Cap
$0.1B
Open
$1.30
Day Range
$1.25 – $1.31
Volume
912,376
Prev Close
$1.33
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.48
Cost of Equity (CAPM)13.11% (VRP-adj)
WACC13.26%
Volatility Risk Premium+155.7pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-11.6%
Book / Price114.8% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$2.30 (Market Anchor value)
SMA 20 / Bollinger Mid$1.56
Bollinger Width / SMA204487.6% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ACAD, ACHC, LFST, MPLT, SUPN (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
94%
20-Day Fair Value
≈ by Nov 25, 2026
ACTIVE
$1.30
α +1.5% rank 98%
conviction
78%
40-Day Fair Value
≈ by Dec 24, 2026
ACTIVE
$1.31
α +2.5% rank 99%
conviction
77%
60-Day Fair Value
≈ by Jan 22, 2027
ACTIVE
$1.34
α +4.9% rank 99%
conviction
94%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0% median 35.0× · 4 peers
Peer P/B $3.38 19% median 2.3× · 5 peers
Peer P/S n/a 0% median 2.9× · 4 peers
Market Anchor (SMA50) $2.30 81% stability 85% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
34
List Date
2006-08-02
CIK
0001314052
Next Earnings
2026-11-24 (After-Close)
EPS Forecast
($0.11) (1 est.)
Headquarters
New York, NY
Homepage
https://www.anavex.com

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett sy…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan18.71%-26.06%12.29%-1.24%-23.70%27.72%1.29%
Feb99.39%-0.72%-13.38%-16.42%-8.45%-1.99%9.74%
Mar15.53%16.90%-11.47%-3.60%3.75%-32.23%-1.85%
Apr-21.46%-32.04%-4.35%-27.29%18.45%7.74%-9.83%
May3.32%0.66%12.41%10.03%-19.12%-8.73%-0.24%
Jun83.03%21.48%-10.66%4.98%21.96%-13.09%17.95%
Jul-26.94%-0.39%3.00%65.33%21.11%6.80%11.48%
Aug7.62%-2.94%-3.07%-8.51%-13.93%-5.08%-4.32%
Sep-11.23%6.94%-17.51%4.03%-6.12%-29.62%-8.92%
Oct4.40%16.02%-12.26%21.69%-11.54%-32.28%*-2.33%
Nov-4.15%-28.87%28.29%38.41%-50.52%---3.37%
Dec-3.18%4.40%22.99%15.24%-6.81%--6.53%
Total174.65%-36.48%-5.69%104.12%-66.20%-64.97%17.57%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.56
SMA 50: $2.30
SMA 200: $3.16
Current: $1.28
EMA 12: $1.43
EMA 26: $1.71
MACD: -0.2831 | Signal: 0.0192
BEARISH
ADX (14): 57.44
STRONG TREND
+DI: 8.39
−DI: 41.60

Momentum Oscillators

RSI (14): 21.67
OVERSOLD
Stoch %K: 31.90
Stoch %D: 31.00
Williams %R: -70.21

Volume & Volatility

BB Upper: $2.10
BB Lower: $1.01
NEUTRAL
OBV: -53,245,217
Vol SMA 20: 1,529,599
Vol ROC: -23.50%
ATR: $0.12
True Range: $0.08
HV 20: 83.5%
HV 30: 74.4%
HV 60: 76.3%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BEARISH (Confidence Level: 6/10)

Key Drivers:

  • Weak technical trend with multiple downward movements
  • High volatility, indicating a high level of uncertainty and risk
  • Negative news sentiment and recent headlines highlighting company issues

Primary Risks:

  • Continued decline in stock price due to market conditions and company performance
  • Potential for further volatility and increased risk for investors

Investment Thesis:

The recent technical trend suggests a bearish momentum with multiple downward movements. The combination of high volatility, negative news sentiment, and recent headlines highlighting company issues contributes to this assessment. Investors should consider the potential risks and rewards before making an investment decision.

Recent News Sentiment Impact:

The recent headlines have been largely negative, contributing to the overall bearish sentiment. The only positive headline was related to Anavex Life Sciences' compliance with Nasdaq's periodic filing requirement.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) = BEARISH; Medium-term (1-3 months) = NEUTRAL; Long-term (3-12 months) = BEARISH

Support/Resistance Levels:

  • Lower band of Bollinger Bands: $2.31
  • Middle line of Bollinger Bands: $2.92
  • Upper band of Bollinger Bands: $3.53

Momentum Signals: RSI interpretation: 30.59 (neutral) MACD signal: -0.14 (bearish) Bollinger Bands position: neutral

Volume Analysis:

  • Volume SMA 20: 736168.35
  • On-Balance Volume (OBV): -42592893.25
  • Volume Rate of Change: -35.40%

News & Sentiment Analysis

Recent Headlines Summary:

The recent headlines highlight company issues and negative sentiment, contributing to the bearish trend.

Sentiment Assessment: NEGATIVE

Catalyst Identification:

  • None significant in the short term

Market Narrative:

The market narrative is driven by the bearish technical trend, high volatility, and negative news sentiment.

Risk & Volatility Assessment

Risk Assessment:

Beta: 1.71 (high risk) Volatility Regime: Current (83.0%) > Historical (70.2%) Options Market Signals: IV Rank: 59.1% (medium) Put/Call ratios: 0.15 (bullish)

Downside Protection:

Support levels: $2.31, $2.92

Market Context & Positioning

Sector Performance:

Anavex Life Sciences is not a significant player in its sector, contributing to the bearish trend.

Institutional Activity:

Recent volume patterns suggest institutional interest is low.

Correlation Analysis: R-squared interpretation: 0.25 (low correlation with market)

Relative Valuation:

Position within trading range: Bearish

Key Levels & Action Items

Critical Price Levels:

  • Lower band of Bollinger Bands: $2.31
  • Middle line of Bollinger Bands: $2.92

Breakout/Breakdown Levels:

  • Resistance level: $3.53
  • Support level: $2.31

Time-Sensitive Catalysts:

  • None significant in the short term

Risk Management:

Stop-loss levels and position sizing considerations will depend on individual investor risk tolerance.

Please note that this report is for informational purposes only and should not be considered investment advice.

Generated
News
All AVXL news →
Earnings History
4 of 4 under expected move
Avg Expected Move
20.21%
Avg Actual Move
8.03%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-05-09 After-Close 9.79% 1.80% 0.18x Within
2025-11-25 Pre-Market 39.77% 12.34% 0.31x Within
2026-02-09 After-Close 10.92% 8.97% 0.82x Within
2026-08-25 After-Close 20.37% 8.99% 0.44x Within

Earnings calendar: this week’s reports with expected vs actual moves →

AVXL Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $0.80
7-DTE Move: $0.80
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 55
Put Volume: 3
P/C Volume: 0.055
BULLISH
Call OI: 229
Put OI: 11
P/C OI: 0.048
Total OI: 240

ATM Options Pricing

ATM Call: $0.42
ATM Put: $0.38
Call %: 33.2%
Put %: 29.3%

Chain Summary

Chain Volume: 1,196
Chain OI: 25,343
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 14th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
14%
vs own history
GEX tilt
-0.87
OI-weighted, today
Vanna tilt
-0.89
δ-sensitivity to IV
Charm tilt
+0.86
δ-decay vs time
Vanna tilt -0.89: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.86: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 5 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 221.7% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.80Oct 26
Beta Analysis

Risk Metrics

Beta: 1.8035
Alpha: -170.86%
Correlation: 0.2573
R-Squared: 6.6%
Stock Volatility: 89.3%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own AVXL
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$852K
0.00%
#3884 of 6285-41.2%13F
Point72 Hedge fund
Steve Cohen
$408K
0.00%
#1678 of 1945new13F
Millennium Management Hedge fund
Izzy Englander
$157K
0.00%
#3539 of 3716new13F
Rockefeller Capital Management Family office
Rockefeller family
$34K
0.00%
#3529 of 4729-27.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

AVXL Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 86,193,315 (as of 2025-12-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

187 filers41,940,839 shares$114.44M value48.66% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 8,055,628 $20.86M 18.23% 9.35% 2026-06-30
2 Vanguard Group Inc Custodian 5,028,534 $17.90M 15.64% 5.83% 2025-12-31
3 Vanguard Capital Management LLC 4,054,589 $10.50M 9.18% 4.70% 2026-06-30
4 Two Sigma Investments, LP Custodian 3,046,538 $7.89M 6.89% 3.53% 2026-06-30
5 Geode Capital Management, LLC Custodian 2,407,473 $6.24M 5.45% 2.79% 2026-06-30
6 State Street Corp 1,922,770 $4.98M 4.35% 2.23% 2026-06-30
7 FEDERATED HERMES, INC. 1,071,809 $2.78M 2.43% 1.24% 2026-06-30
8 AQR Capital Management, LLC Custodian 963,014 $2.49M 2.18% 1.12% 2026-06-30
9 Vanguard Portfolio Management LLC 948,633 $2.46M 2.15% 1.10% 2026-06-30
10 Summit Financial, LLC 909,430 $2.36M 2.06% 1.06% 2026-06-30
11 Goldman Sachs Group Inc Custodian 890,634 $2.31M 2.02% 1.03% 2026-06-30
12 Marshall Wace, LLP Custodian 889,523 $2.30M 2.01% 1.03% 2026-06-30
13 Northern Trust Corp Custodian 784,494 $2.03M 1.78% 0.91% 2026-06-30
14 Barclays PLC Custodian 754,226 $1.95M 1.71% 0.88% 2026-06-30
15 Charles Schwab Investment Management, Inc. 734,795 $1.90M 1.66% 0.85% 2026-06-30
16 Bank of America Corp Custodian 654,295 $1.69M 1.48% 0.76% 2026-06-30
17 Vanguard Fiduciary Trust Co 621,451 $1.61M 1.41% 0.72% 2026-06-30
18 UBS Group AG Custodian 620,374 $1.61M 1.40% 0.72% 2026-06-30
19 Private Advisor Group, LLC 504,000 $1.31M 1.14% 0.58% 2026-06-30
20 Sheets Smith Investment Management 135,948 $1.21M 1.06% 0.16% 2025-09-30
21 LPL Financial LLC Custodian 406,109 $1.05M 0.92% 0.47% 2026-06-30
22 Stifel Financial Corp Custodian 332,597 $861.43K 0.75% 0.39% 2026-06-30
23 Citadel Advisors LLC Custodian 329,115 $852.41K 0.74% 0.38% 2026-06-30
24 Susquehanna International Group, LLP Custodian 319,529 $827.58K 0.72% 0.37% 2026-06-30
25 Bank of New York Mellon Corp Custodian 288,199 $746.43K 0.65% 0.33% 2026-06-30
13 filers$4.10M notional
# Filer Notional Value % of Total Period
1 GREAT POINT PARTNERS LLC $1.35M 32.89% 2026-06-30
2 Wolverine Trading, LLC Custodian $1.31M 31.93% 2025-09-30
3 Citadel Advisors LLC Custodian $560.22K 13.65% 2026-06-30
4 IMC-Chicago, LLC Custodian $231.55K 5.64% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $208.75K 5.09% 2026-06-30
6 Watts Gwilliam & Co., LLC $126.08K 3.07% 2025-09-30
7 Walleye Capital LLC $125.10K 3.05% 2026-06-30
8 Simplex Trading, LLC Custodian $95.05K 2.32% 2026-06-30
9 Susquehanna International Group, LLP Custodian $33.41K 0.81% 2026-06-30
10 Jane Street Group, LLC Custodian $26.68K 0.65% 2026-06-30
11 SUMMIT SECURITIES GROUP LLC $20.89K 0.51% 2026-06-30
12 Strategic Family Wealth Counselors, L.L.C. $15.54K 0.38% 2026-06-30
13 Creative Planning Custodian $600 0.01% 2026-06-30
7 filers$1.48M notional
# Filer Notional Value % of Total Period
1 Wolverine Trading, LLC Custodian $674.70K 45.70% 2025-09-30
2 Susquehanna International Group, LLP Custodian $355.35K 24.07% 2026-06-30
3 Citadel Advisors LLC Custodian $263.40K 17.84% 2026-06-30
4 Simplex Trading, LLC Custodian $135.20K 9.16% 2026-06-30
5 IMC-Chicago, LLC Custodian $31.60K 2.14% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $14.50K 0.98% 2026-06-30
7 Walleye Capital LLC $1.55K 0.11% 2026-06-30

AVXL Insider Trading (Form 4)

Latest: 2026-09-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-28 Sandra Boenisch PFO & Treasurer Grant (A) +95,000 opt — EDGAR
2026-01-09 Sandra Boenisch PFO & Treasurer Grant (A) +12,500 opt — EDGAR
2026-01-09 Christopher U Missling President and CEO Grant (A) +125,000 opt — EDGAR
2025-10-03 Christopher U Missling President and CEO Grant (A) +125,000 opt — EDGAR
2025-10-03 Sandra Boenisch PFO & Treasurer Grant (A) +12,500 opt — EDGAR
2025-09-12 Christopher U Missling President and CEO Mixed +42,452 $7.02 -$444.6K EDGAR
2025-08-22 Sandra Boenisch PFO & Treasurer Grant (A) +12,500 opt — EDGAR
2025-08-22 Christopher U Missling President and CEO Grant (A) +125,000 opt — EDGAR
2025-06-09 Steffen Thomas Director Mixed +38,651 $2.87 $45 EDGAR
2025-04-30 Christopher U Missling President and CEO Grant (A) +125,000 opt — EDGAR
2025-04-30 Sandra Boenisch PFO & Treasurer Grant (A) +12,500 opt — EDGAR
2025-04-02 Peter D.O. Donhauser Director Grant (A) +50,000 opt — EDGAR
2025-04-02 Jiong Ma Director Grant (A) +50,000 opt — EDGAR
2025-04-02 Athanasios Skarpelos Director Grant (A) +50,000 opt — EDGAR
2025-04-02 Claus Vander Velden Director Grant (A) +50,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

AVXL Insider Holdings

5 insiders · @ $1.28
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Christopher U Missling President and CEO 1,510,165 $1.93M -$3.80M 49 2026-01-09
2 Athanasios Skarpelos Director 1,356,458 $1.74M -$453.0K 11 2025-04-02
3 Sandra Boenisch PFO & Treasurer 47,963 $61.4K -$4.42M 19 2026-09-28
4 Steffen Thomas Director 43,651 $55.9K $22.6K 11 2025-06-09
5 Peter D.O. Donhauser Director 5,000 $6.4K $36.0K 11 2025-04-02
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

AVXL Board & Officers

As of SEC filings through Oct 5, 2026

Directors 8

Officers 1

Changes in the last 10 years (25)
Sep 24, 2026Gautam Patel became a director
Sep 24, 2026Adrian Senderowicz became a director
May 11, 2026The company announced the departure of Terrie Kellmeyer as Interim CEO in an SEC filing
May 4, 2026Terrie Kellmeyer became Interim CEO
Feb 23, 2026Axel Paeger became a director
Jul 3, 2025The company announced the departure of Christopher U Missling from the board in an SEC filing
Jul 3, 2025The company announced the departure of Christopher U Missling as President and CEO in an SEC filing
Apr 2, 2025Steffen Thomas first listed as a director in an SEC filing
Apr 2, 2025Claus Vander Velden first listed as a director in an SEC filing
Apr 2, 2025Athanasios Skarpelos first listed as a director in an SEC filing
Dec 6, 2024Sandra Boenisch first listed as PFO & Treasurer in an SEC filing
Dec 6, 2024Christopher U Missling first listed as a director in an SEC filing
Dec 6, 2024Christopher U Missling first listed as President and CEO in an SEC filing
Feb 23, 2024Steffen Thomas reported in an SEC filing no longer being a director
Feb 23, 2024Claus Vander Velden reported in an SEC filing no longer being a director
Feb 23, 2024Athanasios Skarpelos reported in an SEC filing no longer being a director
Jan 12, 2024Sandra Boenisch reported in an SEC filing no longer being PFO & Treasurer
Jan 12, 2024Christopher U Missling reported in an SEC filing no longer being a director
Jan 12, 2024Christopher U Missling reported in an SEC filing no longer being President and CEO
May 25, 2021Jiong Ma became a director
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

AVXL Proposed Insider Sales (Form 144)

Latest: 2024-03-28
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-03-28 MISSLING CHRISTOPHER U Officer 73,380 $371.3K 2024-03-28 Charles Schwab Corp — EDGAR
2023-06-28 MISSLING CHRISTOPHER U Officer 268,000 $2.14M 2023-06-28 Charles Schwab Corp. — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
33 ETFs hold AVXL
25 shown · $18.14M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $5.9M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $3.1M $74.6B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $2.2M — 2026-09-30
4 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $1.3M — 2026-05-31
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.1M — 2026-09-30
6 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $974,095 $13.9B 2026-10-23
7 IBB iShares Biotechnology ETF iShares (BlackRock) 0.01% $905,280 $10.7B 2026-10-23
8 VHT Vanguard Health Care ETF Vanguard 0.00% $546,860 — 2026-09-30
9 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.03% $371,115 $1.2B 2026-10-23
10 SBIO ALPS Medical Breakthroughs ETF Nport 0.18% $289,432 — 2026-05-31
11 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.00% $271,587 $13.7B 2026-10-23
12 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.01% $232,657 $4.2B 2026-10-23
13 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $208,828 — 2026-05-31
14 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $165,602 $96.5B 2026-10-23
15 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $156,538 — 2026-07-31
16 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $142,832 — 2026-09-30
17 RSSL Global X Russell 2000 ETF Global X 0.00% $56,822 — 2026-10-26
18 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.00% $35,021 — 2026-09-30
19 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $34,670 — 2026-10-23
20 ASD Defiance Autism Impact ETF Nport 2.53% $34,229 — 2026-06-30
21 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $26,539 $20.4B 2026-10-23
22 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $12,443 — 2026-09-30
23 IBRN iShares Neuroscience and Healthcare ETF iShares (BlackRock) 0.19% $11,862 $6.3M 2026-10-23
24 MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF Nport 0.00% $10,620 — 2026-05-31
25 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.00% $9,889 $3.2B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.46
TTM Revenue
—
TTM Net Income
$-39.95M
TTM Op. Cash Flow
$-34.08M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262025-12-31—$-5.68M$-0.06$-7.15M
Q4 '252025-09-30—$-9.83M$-0.11$-8.60M
Q3 '252025-06-30—$-13.24M$-0.16$-12.46M
Q2 '252025-03-31—$-11.20M$-0.13$-5.86M
Q1 '252024-12-31—$-12.11M$-0.14$-12.12M
Q4 '242024-09-30—$-11.62M$-0.14$-6.66M
Q3 '242024-06-30—$-12.21M$-0.14$-5.18M
Q2 '242024-03-31—$-10.55M$-0.13$-11.66M
Q1 '242023-12-31—$-8.62M$-0.11$-7.32M
Q4 '232023-09-30—$-10.15M$-0.13$-5.85M
Q3 '232023-06-30—$-11.28M$-0.14$-7.65M
Q2 '232023-03-31—$-13.11M$-0.17$-8.49M
Q1 2026 • period ending 2025-12-31 • filed 2026-02-09
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.87
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-31.5%
ROA
-30.0%
Div Yield
0.00%
FCF Yield
-30.89%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$110.33M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
13.57M
SI % of Float
15.18%
Days to Cover
13.56
Short Vol Ratio
57.4%
Free Float
89.39M
Float %
96.4%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14